Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023. “Clinical and translational medicine data for our lead asset…
Click here to view original post